Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Trials of longer duration are needed to assess the long-term effectiveness and safety of dupilumab. (Funded by Sanofi and Regeneron Pharmaceuticals; SOLO 1 ClinicalTrials.gov number, NCT02277743 ...

New findings from the EVEREST Phase 4 trial presented at the 2025 EAACI Congress reveal that Dupixent (dupilumab ... 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ...

Sanofi and Regeneron are studying dupilumab in ... For more information on dupilumab clinical trials please visit www.clinicaltrials.gov. Tell your healthcare provider about all the medicines ...

Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab ...

PARIS-- French drug giant Sanofi (SAN.FR) and U.S. partner Regeneron Pharmaceuticals REGN said a one-year phase three trial study showed a treatment combining their drug dupilumab with topical ...

Sanofi and Regeneron have put their experimental antibody dupilumab into a Phase III trial assessing its potential in uncontrolled persistent asthma, which the firms hope will serve as one of the ...

Results announced this week of a clinical trial testing the drug dupilumab, made by the biotechnology company Regeneron Pharmaceuticals (REGN) and global pharmaceutical company Sanofi (SNY ...

Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpointsDupixent demonstrated significant clinical and anatomic improv ...